Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Mol Neurobiol. 2014 Sep 9;52(1):456–463. doi: 10.1007/s12035-014-8887-2

Fig. 2.

Fig. 2

The combined application of GV-58 and 3,4-DAP completely restores the magnitude of neurotransmitter release at LEMS model mouse NMJs. a Structure of GV-58 (left, blue) and 3,4-DAP (right, green). b Sample EPP traces from a NMJ of a control serum-treated mouse (quantal content = 107.5 ± 3.6; left), from a LEMS model NMJ before (quantal content = 26.7 ± 1.4) and after application of 50 µM GV-58 (quantal content = 48.4 ± 2.7; middle), and from a LEMS model NMJ before drug application, following application of 1.5 µM 3,4-DAP (quantal content = 49.0 ± 4.4) and following application of 50 µM GV-58 plus 1.5 µM 3,4-DAP (quantal content = 105.1 ± 4.0; right) [70]. a Modified from Ref. [15]; b modified from Ref. [70]